brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Company profile
Ticker
BCLI
Exchange
Website
CEO
Chaim Lebovits
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BRAINSTORM CELL THERAPEUTICS INC, GOLDEN HAND RESOURCES INC, WIZBANG TECHNOLOGIES INC
SEC CIK
Corporate docs
Subsidiaries
BrainStorm Cell Therapeutics Ltd. • Advanced Cell Therapies Ltd. • BrainStorm Cell Therapeutics UK Ltd. • Brainstorm Cell Therapeutics Limited ...
IRS number
208133057
BCLI stock data
Latest filings (excl ownership)
8-K
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
16 Apr 24
8-K
Other Events
11 Apr 24
8-K
BrainStorm Cell Therapeutics Announces Agreement with FDA on a
9 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
8-K
Entry into a Material Definitive Agreement
2 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
1 Apr 24
8-K
BrainStorm Issues 2023 Letter to Shareholders
20 Dec 23
DEFA14A
Additional proxy soliciting materials
22 Nov 23
8-K
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS
22 Nov 23
Transcripts
BCLI
Earnings call transcript
2023 Q3
14 Nov 23
BCLI
Earnings call transcript
2023 Q2
14 Aug 23
BCLI
Earnings call transcript
2023 Q1
15 May 23
BCLI
Earnings call transcript
2022 Q4
30 Mar 23
BCLI
Earnings call transcript
2022 Q4
27 Mar 23
BCLI
Earnings call transcript
2022 Q3
14 Nov 22
BCLI
Earnings call transcript
2022 Q2
15 Aug 22
BCLI
Earnings call transcript
2022 Q1
16 May 22
BCLI
Earnings call transcript
2021 Q4
28 Mar 22
BCLI
Earnings call transcript
2021 Q3
15 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.22 mm | 1.22 mm | 1.22 mm | 1.22 mm | 1.22 mm | 1.22 mm |
Cash burn (monthly) | (no burn) | 243.50 k | 2.01 mm | 1.80 mm | 2.14 mm | 1.82 mm |
Cash used (since last report) | n/a | 1.62 mm | 13.39 mm | 11.95 mm | 14.22 mm | 12.10 mm |
Cash remaining | n/a | -398.60 k | -12.17 mm | -10.73 mm | -13.00 mm | -10.88 mm |
Runway (months of cash) | n/a | -1.6 | -6.0 | -6.0 | -6.1 | -6.0 |
Institutional ownership, Q3 2023
10.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 59 |
Opened positions | 12 |
Closed positions | 10 |
Increased positions | 15 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 775.51 mm |
Total shares | 7.38 mm |
Total puts | 107.60 k |
Total calls | 374.00 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Abbhi Investments | 2.43 mm | $0.00 |
Vanguard | 1.42 mm | $284.80 mm |
BLK Blackrock | 467.41 k | $93.53 mm |
Liberty Wealth Management | 352.62 k | $71.00 k |
Geode Capital Management | 310.78 k | $62.22 mm |
Renaissance Technologies | 203.60 k | $41.00 k |
GTS Securities | 202.72 k | $40.54 mm |
Millennium Management | 175.50 k | $35.12 mm |
Daly Joseph Patrick | 165.00 k | $975.00 k |
Caldwell Sutter Capital | 157.01 k | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 24 | Alla Patlis | Common Stock | Grant | Acquire A | No | No | 0 | 65,246 | 0.00 | 65,246 |
11 Mar 24 | Lebovits Chaim | Common Stock | Grant | Acquire A | No | No | 0 | 305,198 | 0.00 | 598,493 |
11 Mar 24 | Stacy Lindborg | Common Stock | Grant | Acquire A | No | No | 0 | 241,935 | 0.00 | 423,435 |
11 Mar 24 | Yablonka Uri | Common Stock | Grant | Acquire A | No | No | 0 | 109,426 | 0.00 | 126,969 |
1 Sep 23 | Stacy Lindborg | Common Stock | Buy | Acquire P | No | No | 1.7741 | 11,500 | 20.40 k | 181,500 |
News
Reported Earlier, BrainStorm Cell Therapeutics Announces Management Changes As It Plans Registrational Phase 3b Trial Of NurOwn
17 Apr 24
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
11 Apr 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
9 Apr 24
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
9 Apr 24
Brainstorm Cell Q4 EPS $(0.11) Beats $(0.15) Estimate
1 Apr 24
Press releases
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
16 Apr 24
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
11 Apr 24
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
10 Apr 24
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
9 Apr 24
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
8 Apr 24